Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Cervical Cancer

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 37 articles: HTML format

Single Articles

April 2021
1. BIZZARRI N, Pedone Anchora L, Zannoni GF, Carbone V, et al
   Validation of tumour-free distance as novel prognostic marker in early-stage cervical cancer: a retrospective, single-centre, cohort study.
   Br J Cancer. 2021 Apr 14. pii: 10.1038/s41416-021-01384.
   PubMed     Abstract available
   
   
   
2. KREGTING LM, Kaljouw S, de Jonge L, Jansen EEL, et al
   Effects of cancer screening restart strategies after COVID-19 disruption.
   Br J Cancer. 2021;124:1516-1523.
   PubMed     Abstract available
   
   
   March 2021
3. HALLE MK, Sodal M, Forsse D, Engerud H, et al
   A 10-gene prognostic signature points to LIMCH1 and HLA-DQB1 as important players in aggressive cervical cancer disease.
   Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01305.
   PubMed     Abstract available
   
   
   February 2021
4. CASTANON A, Rebolj M, Pesola F, Sasieni P, et al
   Recovery strategies following COVID-19 disruption to cervical cancer screening and their impact on excess diagnoses.
   Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01275.
   PubMed     Abstract available
   
   
   
5. LITWIN TR, Irvin SR, Chornock RL, Sahasrabuddhe VV, et al
   Infiltrating T-cell markers in cervical carcinogenesis: a systematic review and meta-analysis.
   Br J Cancer. 2021;124:831-841.
   PubMed     Abstract available
   
   
   December 2020
6. CIBULA D, Slama J, Dostalek L, Fischerova D, et al
   Tumour-free distance: a novel prognostic marker in patients with early-stage cervical cancer treated by primary surgery.
   Br J Cancer. 2020 Dec 14. pii: 10.1038/s41416-020-01204.
   PubMed     Abstract available
   
   
   November 2020
7. KAMAL M, Lameiras S, Deloger M, Morel A, et al
   Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site.
   Br J Cancer. 2020 Nov 16. pii: 10.1038/s41416-020-01153.
   PubMed     Abstract available
   
   
   October 2020
8. ZHANG Y, Yu M, Jing Y, Cheng J, et al
   Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer.
   Br J Cancer. 2020 Oct 22. pii: 10.1038/s41416-020-01123.
   PubMed     Abstract available
   
   
   
9. ARROYO MUHR LS, Lagheden C, Lei J, Eklund C, et al
   Deep sequencing detects human papillomavirus (HPV) in cervical cancers negative for HPV by PCR.
   Br J Cancer. 2020 Oct 6. pii: 10.1038/s41416-020-01111.
   PubMed     Abstract available
   
   
   September 2020
10. MO XT, Leung TH, Tang HW, Siu MK, et al
    CD109 mediates tumorigenicity and cancer aggressiveness via regulation of EGFR and STAT3 signalling in cervical squamous cell carcinoma.
    Br J Cancer. 2020;123:833-843.
    PubMed     Abstract available
    
    
    August 2020
11. KYRGIOU M, Arbyn M, Bergeron C, Bosch FX, et al
    Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC).
    Br J Cancer. 2020;123:510-517.
    PubMed     Abstract available
    
    
    May 2020
12. LEI J, Ploner A, Lehtinen M, Sparen P, et al
    Impact of HPV vaccination on cervical screening performance: a population-based cohort study.
    Br J Cancer. 2020 May 4. pii: 10.1038/s41416-020-0850.
    PubMed     Abstract available
    
    
    April 2020
13. JEDY-AGBA E, Joko WY, Liu B, Buziba NG, et al
    Trends in cervical cancer incidence in sub-Saharan Africa.
    Br J Cancer. 2020 Apr 27. pii: 10.1038/s41416-020-0831.
    PubMed     Abstract available
    
    
    
14. HASHIM D, Engesaeter B, Baadstrand Skare G, Castle PE, et al
    Real-world data on cervical cancer risk stratification by cytology and HPV genotype to inform the management of HPV-positive women in routine cervical screening.
    Br J Cancer. 2020 Apr 3. pii: 10.1038/s41416-020-0790.
    PubMed     Abstract available
    
    
    
15. ARBYN M, Rezhake R, Yuill S, Canfell K, et al
    Triage of HPV-positive women in Norway using cytology, HPV16/18 genotyping and HPV persistence.
    Br J Cancer. 2020 Apr 3. pii: 10.1038/s41416-020-0787.
    PubMed     Abstract available
    
    
    August 2019
16. LECAVALIER-BARSOUM M, Chaudary N, Han K, Pintilie M, et al
    Correction: Targeting CXCL12/CXCR4 and myeloid cells to improve the therapeutic ratio in patient-derived cervical cancer models treated with radio-chemotherapy.
    Br J Cancer. 2019 Aug 9. pii: 10.1038/s41416-019-0545.
    PubMed     Abstract available
    
    
    June 2019
17. LECAVALIER-BARSOUM M, Chaudary N, Han K, Pintilie M, et al
    Targeting CXCL12/CXCR4 and myeloid cells to improve the therapeutic ratio in patient-derived cervical cancer models treated with radio-chemotherapy.
    Br J Cancer. 2019 Jun 26. pii: 10.1038/s41416-019-0497.
    PubMed     Abstract available
    
    
    
18. PLUMMER C, Michael A, Shaikh G, Stewart M, et al
    Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK.
    Br J Cancer. 2019 Jun 11. pii: 10.1038/s41416-019-0481.
    PubMed     Abstract available
    
    
    April 2019
19. HORN J, Denecke A, Luyten A, Rothe B, et al
    Reduction of cervical cancer incidence within a primary HPV screening pilot project (WOLPHSCREEN) in Wolfsburg, Germany.
    Br J Cancer. 2019 Apr 16. pii: 10.1038/s41416-019-0453.
    PubMed     Abstract available
    
    
    November 2018
20. GILBERT DC, Wakeham K, Langley RE, Vale CL, et al
    Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis.
    Br J Cancer. 2018 Nov 28. pii: 10.1038/s41416-018-0273.
    PubMed     Abstract available
    
    
    October 2018
21. ARROYO-MUHR LS, Lagheden C, Hultin E, Eklund C, et al
    Human papillomavirus type 16 genomic variation in women with subsequent in situ or invasive cervical cancer: prospective population-based study.
    Br J Cancer. 2018 Oct 22. pii: 10.1038/s41416-018-0311.
    PubMed     Abstract available
    
    
    August 2018
22. AOKI Y, Ochiai K, Lim S, Aoki D, et al
    Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistent cervical cancer.
    Br J Cancer. 2018 Aug 3. pii: 10.1038/s41416-018-0206.
    PubMed     Abstract available
    
    
    March 2018
23. LAGHEDEN C, Eklund C, Lamin H, Kleppe SN, et al
    Nationwide comprehensive human papillomavirus (HPV) genotyping of invasive cervical cancer.
    Br J Cancer. 2018 Mar 21. pii: 10.1038/s41416-018-0053.
    PubMed     Abstract available
    
    
    January 2018
24. LAM JUH, Elfstrom KM, Ejegod DM, Pedersen H, et al
    High-grade cervical intraepithelial neoplasia in human papillomavirus self-sampling of screening non-attenders.
    Br J Cancer. 2018;118:138-144.
    PubMed     Abstract available
    
    
    November 2017
25. MARKOVINA S, Wang S, Henke LE, Luke CJ, et al
    Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer.
    Br J Cancer. 2017 Nov 7. doi: 10.1038/bjc.2017.
    PubMed     Abstract available
    
    
    September 2017
26. POLMAN NJ, Veldhuijzen NJ, Heideman DAM, Snijders PJF, et al
    HPV-positive women with normal cytology remain at increased risk of CIN3 after a negative repeat HPV test.
    Br J Cancer. 2017 Sep 7. doi: 10.1038/bjc.2017.
    PubMed     Abstract available
    
    
    August 2017
27. BURGER EA, Pedersen K, Sy S, Kristiansen IS, et al
    Choosing wisely: a model-based analysis evaluating the trade-offs in cancer benefit and diagnostic referrals among alternative HPV testing strategies in Norway.
    Br J Cancer. 2017 Aug 3. doi: 10.1038/bjc.2017.
    PubMed     Abstract available
    
    
    July 2017
28. LAJER CB, Garnaes E, Friis-Hansen L, Norrild B, et al
    The role of miRNAs in human papilloma virus (HPV)-associated cancers: bridging between HPV-related head and neck cancer and cervical cancer.
    Br J Cancer. 2017 Jul 13. doi: 10.1038/bjc.2017.
    PubMed     Abstract available
    
    
    April 2017
29. DICKIE BR, Rose CJ, Kershaw LE, Withey SB, et al
    The prognostic value of dynamic contrast-enhanced MRI contrast agent transfer constant Ktrans in cervical cancer is explained by plasma flow rather than vessel permeability.
    Br J Cancer. 2017 Apr 27. doi: 10.1038/bjc.2017.
    PubMed     Abstract available
    
    
    
30. VIVIANO M, Catarino R, Jeannot E, Boulvain M, et al
    Self-sampling to improve cervical cancer screening coverage in Switzerland: a randomised controlled trial.
    Br J Cancer. 2017 Apr 20. doi: 10.1038/bjc.2017.
    PubMed     Abstract available
    
    
    November 2016
31. SAMUELS S, Balint B, von der Leyen H, Hupe P, et al
    Precision medicine in cancer: challenges and recommendations from an EU-funded cervical cancer biobanking study.
    Br J Cancer. 2016 Nov 22. doi: 10.1038/bjc.2016.
    PubMed     Abstract available
    
    
    
32. CHAUDARY N, Pintilie M, Hedley D, Hill RP, et al
    Hedgehog inhibition enhances efficacy of radiation and cisplatin in orthotopic cervical cancer xenografts.
    Br J Cancer. 2016 Nov 22. doi: 10.1038/bjc.2016.
    PubMed     Abstract available
    
    
    
33. COLDMAN AJ, Gondara L, Smith LW, van Niekerk D, et al
    Disease detection and resource use in the safety and control arms of the HPV FOCAL cervical cancer screening trial.
    Br J Cancer. 2016 Nov 17. doi: 10.1038/bjc.2016.
    PubMed     Abstract available
    
    
    September 2016
34. LANDY R, Pesola F, Castanon A, Sasieni P, et al
    Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case-control study.
    Br J Cancer. 2016 Sep 15. doi: 10.1038/bjc.2016.
    PubMed     Abstract available
    
    
    August 2016
35. CHANDRASEKARAN KS, Sathyanarayanan A, Karunagaran D
    MicroRNA-214 suppresses growth, migration and invasion through a novel target, high mobility group AT-hook 1, in human cervical and colorectal cancer cells.
    Br J Cancer. 2016 Aug 18. doi: 10.1038/bjc.2016.
    PubMed     Abstract available
    
    
    July 2016
36. LUTTMER R, De Strooper LM, Dijkstra MG, Berkhof J, et al
    FAM19A4 methylation analysis in self-samples compared with cervical scrapes for detecting cervical (pre)cancer in HPV-positive women.
    Br J Cancer. 2016 Jul 14. doi: 10.1038/bjc.2016.
    PubMed     Abstract available
    
    
    June 2016
37. SOGAARD M, Farkas DK, Ording AG, Sorensen HT, et al
    Conisation as a marker of persistent human papilloma virus infection and risk of breast cancer.
    Br J Cancer. 2016 Jun 2. doi: 10.1038/bjc.2016.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Cervical Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: